在八十岁前列腺癌患者中cabazitaxel的可行性
Paolo Tralongo1, Sebastiano Bordonaro1, Giuseppe Di Lorenzo2
1Medical Oncology Unit, RAO - Umberto I Hospital, Siracusa, Italy.
Current urology
|July 14, 2023
概括
卡巴西塔克塞尔在80岁以上的老年割抵抗性前列腺癌患者中有效. 剂量调整和老年患者评估可以改善这一群体的安全性和治疗结果.
科学领域:
- 在瘤学瘤学.
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗割前列腺癌 (CRPC) 在老年患者 (≥80岁) 中带来了治疗挑战.
- 对八十岁的CRPC患者评估cabazitaxel的疗效和安全性至关重要.
研究的目的:
- 评估cabazitaxel在患有CRPC的80岁及以上患者的有效性和安全性.
- 探讨剂量修改和老年评估在管理这一患者群体中的作用.
主要方法:
- 意大利11个癌症中心的回顾性研究.
- 包括57名患者 (≥80岁) 以前接受过多塞塔塞尔治疗.
- 使用综合老年病评估 (CGA) 和东部合作瘤学集团 (ECOG) 绩效状态 (PS).
主要成果:
- 疾病控制率为63%;前列腺特异性抗原反应为31.5%.
- 平均整体存活时间为13.1个月,但在易受伤害的患者 (7.2个月) 和PS≥2 (6.8个月) 的患者中减少.
- 3-4级毒性包括中性质减退 (14%) 和腹 (10.5%);10.5%因毒性而停止治疗.
结论:
- 卡巴西塔克塞尔可以安全地给八十岁的CRPC患者使用降低剂量或替代时间表.
- 剂量调整和CGA可以减轻毒性和治疗中断.
- CGA有助于选择合适的老年患者接受cabazitaxel治疗.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K